JP4116431B2 - ラクタム化合物 - Google Patents

ラクタム化合物 Download PDF

Info

Publication number
JP4116431B2
JP4116431B2 JP2002542779A JP2002542779A JP4116431B2 JP 4116431 B2 JP4116431 B2 JP 4116431B2 JP 2002542779 A JP2002542779 A JP 2002542779A JP 2002542779 A JP2002542779 A JP 2002542779A JP 4116431 B2 JP4116431 B2 JP 4116431B2
Authority
JP
Japan
Prior art keywords
methyl
amino
formula
tetrahydro
benzazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002542779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521084A5 (enExample
JP2004521084A (ja
Inventor
トーマス・ミッチェル・コーニグ
ジェイムズ・エドモンド・オーディア
デイビッド・ミッチェル
ステイシー・リー・マクダニエル
リン・アン・ブッチッリ
ゲイリー・ローウェル・エンゲル
ジェイムズ・エイブラハム・エイキンズ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2004521084A publication Critical patent/JP2004521084A/ja
Publication of JP2004521084A5 publication Critical patent/JP2004521084A5/ja
Application granted granted Critical
Publication of JP4116431B2 publication Critical patent/JP4116431B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2002542779A 2000-11-17 2001-11-02 ラクタム化合物 Expired - Fee Related JP4116431B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (3)

Publication Number Publication Date
JP2004521084A JP2004521084A (ja) 2004-07-15
JP2004521084A5 JP2004521084A5 (enExample) 2005-12-22
JP4116431B2 true JP4116431B2 (ja) 2008-07-09

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002542779A Expired - Fee Related JP4116431B2 (ja) 2000-11-17 2001-11-02 ラクタム化合物

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN100516047C (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2432102A (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1867636B1 (en) 2005-04-08 2013-06-05 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272305A1 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS

Also Published As

Publication number Publication date
WO2002040451A2 (en) 2002-05-23
US20040248878A1 (en) 2004-12-09
DZ3454A1 (fr) 2002-05-23
ECSP034598A (es) 2003-06-25
ZA200303411B (en) 2004-08-02
EP1353910B1 (en) 2007-05-23
PE20020798A1 (es) 2002-09-06
JP2004521084A (ja) 2004-07-15
UA77165C2 (en) 2006-11-15
AR031356A1 (es) 2003-09-17
ATE362919T1 (de) 2007-06-15
PL360991A1 (en) 2004-09-20
BR0115424A (pt) 2003-10-21
EA006919B1 (ru) 2006-04-28
EA200300579A1 (ru) 2003-12-25
TWI235151B (en) 2005-07-01
CN100516047C (zh) 2009-07-22
DK1353910T3 (da) 2007-09-10
PL211018B1 (pl) 2012-03-30
AU2002224321B2 (en) 2006-10-19
CA2425497C (en) 2010-08-17
SV2003000741A (es) 2003-01-13
HUP0301862A3 (en) 2007-09-28
CA2425497A1 (en) 2002-05-23
CZ20031340A3 (cs) 2004-06-16
PT1353910E (pt) 2007-08-20
DE60128587D1 (de) 2007-07-05
IL155275A0 (en) 2003-11-23
NO20032215L (no) 2003-07-16
HRP20030385A2 (en) 2003-08-31
DE60128587T2 (de) 2008-01-31
HUP0301862A2 (hu) 2003-09-29
WO2002040451A3 (en) 2003-08-28
CN1575282A (zh) 2005-02-02
CY1106682T1 (el) 2012-05-23
NO325217B1 (no) 2008-02-25
CN101624372A (zh) 2010-01-13
SK287794B6 (sk) 2011-10-04
EP1353910A2 (en) 2003-10-22
MXPA03004250A (es) 2003-09-22
MY141607A (en) 2010-05-31
NO20032215D0 (no) 2003-05-15
ES2286162T3 (es) 2007-12-01
SK5432003A3 (en) 2004-09-08
KR20030045194A (ko) 2003-06-09
AU2432102A (en) 2002-05-27

Similar Documents

Publication Publication Date Title
CA2427227C (en) Lactam compound
JP4116431B2 (ja) ラクタム化合物
JP2004521084A5 (enExample)
AU2002224321A1 (en) Lactam compound
US7468365B2 (en) Lactam compound
EP1345955B1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
US20040077627A1 (en) Lactam compound
NZ525365A (en) Lactam compound
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080417

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140425

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees